Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.

NCT ID NCT07720596

Disease control Sponsor: Charles University, Czech Republic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study uses health records from over 1.8 million adults in the Czech Republic to see if the antiviral drug molnupiravir lowers the risk of dying from COVID-19 during the Omicron wave. Researchers compare people who received molnupiravir plus standard care with similar patients who received standard care alone. The goal is to determine whether this oral treatment can reduce deaths from COVID-19 and all causes within three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
molnupiravir, an antiviral drug taken as capsules twice daily for five days
What this could lead to
If molnupiravir is linked to lower death rates, it could support its use as a treatment for mild-to-moderate COVID-19 in high-risk patients.
What could go wrong
This is a retrospective analysis, not a controlled trial, so results may be influenced by unmeasured factors. The drug may show no clear benefit or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,814,551 people

The number who actually took part.

Started

Jan 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All adult patients with confirmed SARS-CoV-2 infection recorded in Czech nationwide health registry data from January 1, 2022, through December 31, 2024.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult infection episodes among patients aged 20 years or older. * Confirmed acute SARS-CoV-2 positivity recorded in the Infectious Disease Information System (ISIN) during the Omicron-era study period. * Eligible for analysis at time zero, defined as the date of molnupiravir dispensing for treated patients and the matched date for controls. * Mild-to-moderate COVID-19 suitable for oral antiviral treatment, operationalized by excluding those already dead, in ICU, or receiving mechanical ventilation at time zero. Exclusion Criteria: * Age below 20 years at time of positivity. * Death, ICU hospitalization, or mechanical ventilation at time zero. * Receipt of molnupiravir, monoclonal antibodies, remdesivir, or nirmatrelvir/ritonavir within 14 days before positivity. * Receipt of molnupiravir, monoclonal antibodies, remdesivir, or nirmatrelvir/ritonavir within 14 days after the qualifying SARS-CoV-2 positivity, but outside the treatment-initiation eligibility window according to the SmPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 SARS-CoV 2

Contacts and locations

Locations

  • Department of Pharmacology, Third Faculty of Medicine, Charles University

    Prague, 10000, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.